NeuMoDx™

📍 Ann Arbor, United States👥 93 employees💰 Last funded Apr 2012
The NeuMoDx™ Molecular systems are a family of scalable platforms that fully integrate the entire molecular diagnostic process from “sample to result.” The NeuMoDx™ 288 and the NeuMoDx™ 96 Molecular systems are fully automated, continuous random-access analyzers that utilize proprietary NeuDry reagent technology, which integrates magnetic particle affinity capture and real time Polymerase Chain Reaction (PCR) chemistry in a multi-sample microfluidic cartridge. This technology, combined with a platform, uniquely incorporates robotics and microfluidics that result in higher throughput, improved performance, and increased efficiency by eliminating the waste associated with technologies that require reconstitution of lyophilized reagents. NeuMoDx™ has recently received FDA 510(k) clearance for its NeuMoDx™ GBS Assay for the detection of Group B Streptococcus (GBS) DNA in antepartum pregnant women and will continue development of tests to detect and monitor sexually transmitted and infectious diseases. Additionally, NeuMoDx™ offers a broad range of general purpose reagents and consumables for use by laboratorians in developing qualitative and quantitative Laboratory Developed Tests (LDTs) for use with the NeuMoDx™ Molecular Systems to detect and amplify DNA and RNA targets. Call 888-301-6639 or email info@neumodx.com.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in NeuMoDx™?
NeuMoDx™ has 1 investors on record on gritt.io.
When did NeuMoDx™ last raise funding?
The most recent investment in NeuMoDx™ recorded on gritt.io was in April 2012.
What industry is NeuMoDx™ in?
NeuMoDx™ operates in Medical Devices. Find similar Medical Devices investors on gritt.io.
Where is NeuMoDx™ based?
NeuMoDx™ is headquartered in Ann Arbor, United States.